Tendyne has announced (pdf) it has secured $25 million in series C financing.

Tendyne Holdings, headquartered in Roseville, Minn., is a clinical stage medical device company focused on the development of minimally invasive therapies for the treatment of mitral regurgitation.

The series C financing was led by VC firm Apple Tree Partners.

Tendyne indicated that the proceeds from the financing will be used for validation of the company’s Transcatheter Mitral Valve Implant to treat mitral regurgitation, including forthcoming clinical trials.